Norinchukin Bank The grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,672 shares of the life sciences company’s stock after acquiring an additional 805 shares during the quarter. Norinchukin Bank The’s holdings in Illumina were worth $2,550,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of ILMN. Advisory Services Network LLC raised its stake in Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 89 shares in the last quarter. Dupont Capital Management Corp acquired a new position in Illumina during the third quarter worth about $153,000. SeaCrest Wealth Management LLC acquired a new position in Illumina during the fourth quarter worth about $154,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Illumina by 113.9% during the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after acquiring an additional 410 shares in the last quarter. Finally, Patten Group Inc. raised its stake in Illumina by 71.1% during the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock worth $172,000 after acquiring an additional 615 shares in the last quarter. 91.12% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Robert S. Epstein sold 1,250 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the sale, the director now directly owns 9,088 shares in the company, valued at $2,058,886.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $212.55, for a total value of $4,251,000.00. Following the completion of the sale, the director now owns 505,980 shares in the company, valued at $107,546,049. The disclosure for this sale can be found here. Insiders sold 95,848 shares of company stock worth $21,414,125 over the last quarter. 0.89% of the stock is currently owned by company insiders.
Several research firms have recently weighed in on ILMN. Canaccord Genuity restated a “buy” rating and set a $265.00 price target (up from $255.00) on shares of Illumina in a report on Wednesday, January 31st. Evercore ISI began coverage on Illumina in a report on Wednesday, January 3rd. They set an “outperform” rating and a $250.00 price target on the stock. BidaskClub cut Illumina from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Leerink Swann boosted their price target on Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, Barclays boosted their price target on Illumina from $200.00 to $215.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $241.39.
Shares of Illumina, Inc. (ILMN) opened at $227.91 on Thursday. Illumina, Inc. has a twelve month low of $158.02 and a twelve month high of $248.97. The company has a market capitalization of $33,305.79, a P/E ratio of 45.95, a P/E/G ratio of 3.00 and a beta of 0.92. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The business had revenue of $778.00 million for the quarter, compared to analysts’ expectations of $752.04 million. During the same period in the prior year, the business posted $0.85 earnings per share. The firm’s revenue was up 25.7% on a year-over-year basis. equities analysts predict that Illumina, Inc. will post 4.59 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/22/illumina-inc-ilmn-shares-bought-by-norinchukin-bank-the.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.